title: Blood-brain barrier damage as a risk factor for corticosteroid-induced psychiatric disorders in systemic lupus erythematosus.
abstract: To clarify the incidence of and risk factors for corticosteroid-induced psychiatric disorders (CIPDs) in patients with systemic lupus erythematosus (SLE), we conducted a prospective study of 161 consecutive episodes in 155 inpatients with a SLE flare who were treated with corticosteroids. A subgroup of these patients, those who experienced a total of 22 episodes with current overt central nervous system manifestations of SLE (CNS-SLE), were excluded from follow-up. Results of clinical, laboratory, and neurologic tests (including electroencephalography, magnetic resonance imaging of the brain, and cerebrospinal fluid [CSF] analysis), performed within a week before corticosteroid administration, were assessed with regard to development of CIPDs. Within 8 weeks of corticosteroid administration, a diagnosis of CIPD was made for 14 (10.1%) of 139 episodes in 135 patients with a non-CNS-SLE flare. Using multiple logistic regression analysis, we identified positive Q(albumin) (CSF/serum albumin ratio; an indicator of blood-brain barrier [BBB] damage) (odds ratio [OR], 33.3; 95% confidence interval [CI], 3.64-304; p=0.002) and low serum levels of complements (OR, 0.91; 95% CI, 0.83-1.00; p=0.047) as independent risk factors for CIPDs. Positive Q(albumin) was detected in 45% (5 of 11) of episodes in which CIPDs developed. Compared with episodes in which no psychiatric events occurred, a higher level of Q(albumin) was found in episodes in which CIPDs developed, and an even higher level was noted in episodes with active CNS-SLE (Jonckheere-Terpstra test, p<0.001). Although no causal links have been proven, the results from the present study raise the possibility that BBB damage may be associated with SLE- and corticosteroid-induced behavioral changes.
authors.affiliation: Department of Psychiatry, Tokyo Women's Medical University School of Medicine, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan. knishimura@psy.twmu.ac.jp
authors.forename: Katsuji
authors.initials: K
authors.lastname: Nishimura
authors.forename: Masayoshi
authors.initials: M
authors.lastname: Harigai
authors.forename: Masako
authors.initials: M
authors.lastname: Omori
authors.forename: Eri
authors.initials: E
authors.lastname: Sato
authors.forename: Masako
authors.initials: M
authors.lastname: Hara
mesh_terms: D000305:Adrenal Cortex Hormones / Q000009:adverse effects* / Q000627:therapeutic use; D000328:Adult; D000418:Albumins / Q000134:cerebrospinal fluid; D001812:Blood-Brain Barrier / Q000293:injuries*; D004569:Electroencephalography; D005260:Female; D006801:Humans; D016015:Logistic Models; D008180:Lupus Erythematosus, Systemic / Q000150:complications* / Q000188:drug therapy / Q000523:psychology; D008279:Magnetic Resonance Imaging; D008297:Male; D001523:Mental Disorders / Q000139:chemically induced* / Q000453:epidemiology* / Q000523:psychology; D009483:Neuropsychological Tests; D011446:Prospective Studies; D012307:Risk Factors
chemical_list: D000305:Adrenal Cortex Hormones; D000418:Albumins